FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions-Reference-Cited by-同舟云学术

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Published:2021-05-27 Issue:20 Volume:27 Page:5452-5456
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kim Janice,Bradford Diana,Larkins Erin,Pai-Scherf Lee H.,Chatterjee Somak,Mishra-Kalyani Pallavi S.,Wearne Emily,Helms Whitney S.,Ayyoub Amal,Bi Youwei,Sun Jielin,Charlab Rosane,Liu Jiang,Zhao Hong,Liang Dun,Ghosh Soma,Philip Reena,Pazdur Richard,Theoret Marc R.,Beaver Julia A.,Singh Harpreet

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group;Annals of Oncology;2024-07

2. Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer;AAPS Open;2024-06-17

3. Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions;Annals of Surgical Oncology;2024-06-07

4. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17

5. A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol;2024-04-16